CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern
Biosensors and Bioelectronics · 2023-06 · 229 · 115238
DOI: 10.1016/j.bios.2023.115238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2023-06. Verfasst von Yunxiang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Center of AMMS, Beijing, 100850, PR China. Hauptthemen laut MEDLINE: COVID-19, Biosensing Techniques. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The continued emergence of SARS-CoV-2 variants of concern (VOCs) has raised great challenges for epidemic prevention and control. A rapid, sensitive, and on-site SARS-CoV-2 genotyping technique is urgently needed for individual diagnosis and routine surveillance. Here, a field-deployable ultrasensitive CRISPR-based diagnostics system, called Chemical additive-Enhanced Single-Step Accurate CRISPR/Cas13 Testing system (CESSAT), for simultaneous screening of SARS-CoV-2 and its five VOCs (Alpha, Beta, Gamma, Delta, and Omicron) within 40 min was reported. In this system, a single-step reverse transcription recombinase polymerase amplification-CRISPR/Cas13a assay was incorporated with optimized extraction-free viral lysis and reagent lyophilization, which could eliminate complicated sample processing steps and rigorous reagent storage conditions. Remarkably, 10% glycine as a chemical additive could improve the assay sensitivity by 10 times, making the limit of detection as low as 1 copy/μL (5 copies/reaction). A compact optic fiber-integrated smartphone-based device was developed for sample lysis, assay incubation, fluorescence imaging, and result interpretation. CESSAT could specifically differentiate the synthetic pseudovirus of SARS-CoV-2 and its five VOCs. The genotyping results for 40 clinical samples were in 100% concordance with standard method. We believe this simple but efficient enhancement strategy can be widely incorporated with existing Cas13a-based assays, thus leading a substantial progress in the development and application of rapid, ultrasensitive, and accurate nucleic acid analysis technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics Center of AMMS, Beijing, 100850, PR China.
- Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, PR China.
- Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, PR China. Electronic address: daieh2008@126.com.
- Bioinformatics Center of AMMS, Beijing, 100850, PR China. Electronic address: rongzhen0525@sina.com.
- Bioinformatics Center of AMMS, Beijing, 100850, PR China. Electronic address: sqwang@bmi.ac.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Chen, H., Gao, H., Wei, H., Wang, Y., Mu, K., Liu, L., Dai, E., Rong, Z., & Wang, S. (2023). CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern. Biosensors and Bioelectronics, 229, 115238. https://doi.org/10.1016/j.bios.2023.115238
Vancouver
Wang Y, Chen H, Gao H, Wei H, Wang Y, Mu K, et al. CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern. Biosensors and Bioelectronics. 2023;229:115238. doi:10.1016/j.bios.2023.115238
BibTeX
@article{Wang2023,
author = {Wang, Yunxiang and Chen, Hong and Gao, Huixia and Wei, Hongjuan and Wang, Yuling and Mu, Kai and Liu, Liyan and Dai, Erhei and Rong, Zhen and Wang, Shengqi},
title = {CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern},
journal = {Biosensors and Bioelectronics},
year = {2023},
volume = {229},
pages = {115238},
doi = {10.1016/j.bios.2023.115238}
}
EUVIMED